Another trial in 54 individuals confirmed its safety over 10 days of intravenous use at doses of up to 5.0g/kg (and up to 25.0g/kg in a single-dose trial)
It is important to note that while preclinical studies suggest promising therapeutic potential, clinical trials in humans are limited
Vendor-channel products operate under varying levels of regulatory oversight depending on their supply chain
GHK-Cu Side Effects and Safety Potential concerns include: Skin irritation, redness, or sensitivity (with topical use) Variable absorption depending on formulation, but newer research has demonstrated that adding in a transport vessel such as liposomes can help with topical absorption (12)
Axelsen M, Sidhu S
Its triple GIP/GLP-1/glucagon agonist mechanism produced the most striking weight-loss numbers ever reported in a Phase 2 trial of an injectable peptide, and its broad TRIUMPH Phase 3 program is poised to expand understanding of how triple receptor modulation affects obesity, diabetes, liver disease, cardiovascular risk, sleep apnea, and musculoskeletal health
